How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...
Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
About Advanced Micro Devices Inc. Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an unusually ambitious goal: building AI systems capable of improving themselves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results